With FDA de­ci­sion loom­ing, GSK sweet­ens the PD-1 pot for dis­cov­ery part­ner Anap­tys­Bio as Hal Bar­ron moves to guard his on­col­o­gy strat­e­gy

Anap­tys­Bio $ANAB CEO Hamza Suria is count­ing up the mon­ey he’s due from Glax­o­SmithK­line.

GSK’s Hal Bar­ron in­her­it­ed a part­ner­ship with Anap­tys­Bio when he bought out Tesaro and gained the PARP drug Ze­ju­la a cou­ple of years ago for $5 bil­lion. And he’s will­ing to pay for the right to try var­i­ous check­point com­bi­na­tion drugs with Ze­ju­la now that the PD-1 he al­so got in the deal is teed up for a like­ly near-term ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER